Fig. 1 · Structure

Documents & Downloads

EP1013

Cat. No. A11212 CAS 223568-55-6

caspase inhibitor

EP1013 is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetes.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Caspase  

EP1013 Research Summary

This section summarizes 2 in vivo studies of EP1013 from 1 published reference. In vivo models include Balb/C donors and chemically diabetic B6 recipients.

EP1013 In Vivo Studies

In Balb/C donor islet allografts transplanted into chemically diabetic B6 recipients, EP1013 treatment produced no prolongation of allograft survival compared with vehicle-treated animals. In the intragraft cell assessment, EP1013 alone yielded 87.8 ± 27.8 cells/HPF and significantly increased regulatory T-cell frequency versus control. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

EP1013 and Islet Allograft Survival

Animal study · Balb/C (H-2d) donors and chemically diabetic B6 (H-2b) recipients [1]

In Balb/C donor islet allografts transplanted into chemically diabetic B6 recipients, EP1013 was administered by medium incubation at 100 μmol/l and s.c. dosing at 3 mg/kg. Mean allograft survival was 18.2 days versus 22.8 days in vehicle-treated animals, with no prolongation of survival.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
islet allograft survivalislet allograft survival EP1013 at 100 μmol/l; 3 mg/kg s.c., days 0–10: mean survival time 18.2 days[1]

Conditions shared by the study groups

Route
incubated in medium; s.c.
Treatment course
Before transplantation; for 2 h; days 0–10
Vehicle
DMSO in sterile saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
EP1013 100 μmol/l; 3 mg/kgvehicle-treated animalsno prolongation of islet allograft survival (mean survival time 18.2 days) compared with vehicle-treated animals (mean survival time 22.8 days, P = NS)[1]
EP1013 100 μmol/l; 3 mg/kg
Model: Balb/C (H-2d) donors and chemically diabetic B6 (H-2b) recipients
Methods and source locations

Compound reported in the paper: EP1013

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESEARCH DESIGNS AND METHODS > Islet transplantation studies. (S6, S7, S8); RESULTS > Combination of EP1013 and CTLA4-Ig results in long-term islet allograft acceptance and operational tolerance. (S27, S28); FIG. 1. legend (S66)

islet allograft survival: islet allograft survival; comparator: vehicle-treated animals — RESEARCH DESIGNS AND METHODS > Islet transplantation studies. (S7, S8); RESULTS > Combination of EP1013 and CTLA4-Ig results in long-term islet allograft acceptance and operational tolerance. (S28)

EP1013 100 μmol/l; 3 mg/kg · RESEARCH DESIGNS AND METHODS > Islet transplantation studies. (S7, S8); RESULTS > Combination of EP1013 and CTLA4-Ig results in long-term islet allograft acceptance and operational tolerance. (S28)

EP1013 and Intragraft Regulatory T Cells

Animal study · Balb/C (H-2d) donors and chemically diabetic B6 (H-2b) recipients; n = 3–4 animals per group [1]

In Balb/C donor islet allografts transplanted into chemically diabetic B6 recipients, EP1013 was administered by medium incubation at 100 μmol/l and s.c. dosing at 3 mg/kg. EP1013 alone yielded 87.8 ± 27.8 cells/HPF, with a significant increase in intragraft regulatory T-cell frequency versus control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Quantification of Foxp3+ cells/HPFintragraft Foxp3+ Treg cells EP1013 at 100 μmol/l; 3 mg/kg s.c., days 0–10; day 11 post-transplant: 87.8 ± 27.8 cells/HPF[1]

Conditions shared by the study groups

Route
incubated in medium; s.c.
Treatment course
Before transplantation; for 2 h; days 0–10; day 11 post-transplant
Vehicle
DMSO in sterile saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
EP1013 100 μmol/l; 3 mg/kgvehicle-treated animalsEP1013, either alone (87.8 ± 27.8 cells/HPF, Fig. 4F); a significant increase in the frequency of intragraft regulatory T-cells (P < 0.01 vs. control and vs. CTLA4-Ig alone by ANOVA)[1]
EP1013 100 μmol/l; 3 mg/kg
Model: Balb/C (H-2d) donors and chemically diabetic B6 (H-2b) recipients; n = 3–4 animals per group
Methods and source locations

Compound reported in the paper: EP1013

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESEARCH DESIGNS AND METHODS > Islet transplantation studies. (S6, S7, S8); RESEARCH DESIGNS AND METHODS > Immunofluorescence. (S13); RESULTS > Caspase inhibitor therapy (EP1013) alters early allogeneic immune responses. (S57, S58); FIG. 1. legend (S66); FIG. 4. legend (S88, S90, S95, S96)

Quantification of Foxp3+ cells/HPF: Quantification of Foxp3+ cells/HPF; comparator: vehicle-treated animals — RESEARCH DESIGNS AND METHODS > Islet transplantation studies. (S7, S8); RESULTS > Caspase inhibitor therapy (EP1013) alters early allogeneic immune responses. (S58); FIG. 4. legend (S88, S95)

EP1013 100 μmol/l; 3 mg/kg · RESEARCH DESIGNS AND METHODS > Islet transplantation studies. (S7, S8); RESULTS > Caspase inhibitor therapy (EP1013) alters early allogeneic immune responses. (S58); FIG. 4. legend (S88, S95)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 223568-55-6
Applications caspase inhibitor
Formula C18H23FN2O6
Molecular Weight 382.38
Synonyms F1013
SMILES
O=C(O)C[C@H](NC([C@H](C(C)C)NC(OCC1=CC=CC=C1)=O)=O)C(CF)=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

EP1013 Research References

  1. [1] Emamaullee JA, Davis J, Pawlick R, et al. Caspase inhibitor therapy synergizes with costimulation blockade to promote indefinite islet allograft survival. Diabetes (2010). PMID: 20332344 DOI: 10.2337/db09-0502 Source material

Added to your cart

View Cart Checkout
Loading...